Johnson & Johnson (JNJ)
J&J to Expand Cancer Pipeline With $1B Firefly Bio Acquisition
JNJ is set to acquire Firefly Bio for $1 billion in cash, adding its Firelink DAC platform and advancing efforts in KRAS-driven cancer treatments.
JNJ and AZN Face Patent Headwinds: Which Stock Looks Stronger Now?
J&J's diversified healthcare business and growth outlook help it stand out against AstraZeneca despite patent and legal challenges.
Will Johnson & Johnson Stock Hit $300 This Year?
Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) has rallied 13.73% year to date and 55.27% over the past year, fueled by oncology blockbusters and a MedTech franchise hitting on every cylinder.
J&J beats lawsuit alleging that talc caused three women's cancer
A Los Angeles jury on Friday sided with Johnson & Johnson in a lawsuit by the families of three women who alleged that the company's talc products caused ovarian cancer, finding that J&J was not negligent when selling cosmetic talc products.
Can JNJ Sustain Growth Amid Patent, Legal and China Risks?
J&J faces Stelara erosion, China MedTech pressure and talc litigation, but targets $100B revenues and faster growth in 2026.
Johnson & Johnson (JNJ) Exceeds Market Returns: Some Facts to Consider
In the latest trading session, Johnson & Johnson (JNJ) closed at $228.17, marking a +2.21% move from the previous day.
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
J&J prostate cancer drug reduces risk of cancer spread and death in late-stage study
Johnson & Johnson's prostate cancer drug Erleada used with hormone-blocking therapy six months before and after prostate surgery improved the chances of eliminating the cancer and reduced the risk of disease progression or death, according to data from a late-stage trial presented on Sunday.
Johnson & Johnson (JNJ) Stock Slides as Market Rises: Facts to Know Before You Trade
Johnson & Johnson (JNJ) reached $225.33 at the closing of the latest trading day, reflecting a -2.37% change compared to its last close.
Is Johnson & Johnson (JNJ) a Buy as Wall Street Analysts Look Optimistic?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
J&J Stock Gains Nearly 12% Year to Date: Buy, Sell or Hold Now?
JNJ is up nearly 12% YTD as strong oncology drug growth, MedTech demand and pipeline advances help offset Stelara patent-loss pressure.
J&J Mastered Cancer Biotech Deals on the Cheap. Can It Stay on the Cutting Edge?
Partnership strategy has produced great pharma bargains—and left the company exposed.
